Related Experiment Videos
Tissue microarray-based analysis shows phospho-beta-catenin expression in malignant melanoma is associated with poor
Eric Kielhorn1, Elayne Provost, Drew Olsen
1Department of Pathology, Yale University School of Medicine, New Haven, CT 06520-8023, USA.
International Journal of Cancer
|December 21, 2002
Summary
Activated beta-catenin, detected by phospho-specific antibodies, shows nuclear localization in melanoma. High nuclear phospho-beta-catenin levels correlate with significantly worse overall survival in melanoma patients.
Area of Science:
- Oncology
- Molecular Biology
- Immunohistochemistry
Background:
- Limited prognostic markers exist for melanoma beyond depth of invasion.
- Beta-catenin signaling activation is implicated in melanoma oncogenesis through mutation or altered localization.
Purpose of the Study:
- To investigate the utility of activated beta-catenin, detected by a phospho-specific antibody, as a prognostic marker in melanoma.
- To correlate phospho-beta-catenin expression with patient outcomes.
Main Methods:
- Immunohistochemical analysis of beta-catenin and phospho-beta-catenin in melanoma tissues.
- Validation of a ser33/37/thr41 phospho-beta-catenin antibody specificity in transfected cells.
- Tissue microarray-based study to assess expression in primary and metastatic lesions.
Main Results:
- Phospho-beta-catenin expression is predominantly nuclear in both cell lines and human tissues.
- Nuclear phospho-beta-catenin was more prevalent in metastatic melanoma lesions compared to primary lesions.
- High levels of nuclear phospho-beta-catenin were significantly associated with worse overall survival (51% vs. 25% at 5 years, p=0.046).
Conclusions:
- Phospho-specific antibodies to beta-catenin identify a distinct subset of melanoma cases.
- Monitoring nuclear phospho-beta-catenin expression may aid in prognostic assessment for malignant melanoma.